vs
CareTrust REIT, Inc.（CTRE）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
CareTrust REIT, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.9倍（$134.9M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 82.5%，领先301.5%），CareTrust REIT, Inc.同比增速更快（55.1% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 46.2%）
本公司是一家英国房地产投资企业，专注于医疗类不动产投资，持有规模庞大的养老护理院资产组合。公司采用房地产投资信托（REIT）架构，在伦敦证券交易所上市，是富时250指数成分股。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CTRE vs RIGL — 直观对比
营收规模更大
CTRE
是对方的1.9倍
$69.8M
营收增速更快
CTRE
高出33.9%
21.2%
净利率更高
RIGL
高出301.5%
82.5%
两年增速更快
RIGL
近两年复合增速
46.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $134.9M | $69.8M |
| 净利润 | $111.3M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 82.5% | 384.0% |
| 营收同比 | 55.1% | 21.2% |
| 净利润同比 | 113.5% | 1769.2% |
| 每股收益（稀释后） | $0.52 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTRERIGL
| Q4 25 | $134.9M | $69.8M | ||
| Q3 25 | $132.4M | $69.5M | ||
| Q2 25 | $112.5M | $101.7M | ||
| Q1 25 | $96.6M | $53.3M | ||
| Q4 24 | $86.9M | $57.6M | ||
| Q3 24 | $77.4M | $55.3M | ||
| Q2 24 | $68.9M | $36.8M | ||
| Q1 24 | $63.1M | $29.5M |
净利润CTRERIGL
| Q4 25 | $111.3M | $268.1M | ||
| Q3 25 | $74.9M | $27.9M | ||
| Q2 25 | $68.5M | $59.6M | ||
| Q1 25 | $65.8M | $11.4M | ||
| Q4 24 | $52.1M | $14.3M | ||
| Q3 24 | $33.4M | $12.4M | ||
| Q2 24 | $10.8M | $-1.0M | ||
| Q1 24 | $28.7M | $-8.2M |
毛利率CTRERIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率CTRERIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | 58.1% | 40.9% | ||
| Q2 25 | 61.3% | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | 43.0% | 25.4% | ||
| Q2 24 | 15.1% | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率CTRERIGL
| Q4 25 | 82.5% | 384.0% | ||
| Q3 25 | 56.6% | 40.2% | ||
| Q2 25 | 60.9% | 58.6% | ||
| Q1 25 | 68.1% | 21.5% | ||
| Q4 24 | 60.0% | 24.9% | ||
| Q3 24 | 43.2% | 22.5% | ||
| Q2 24 | 15.6% | -2.8% | ||
| Q1 24 | 45.6% | -27.9% |
每股收益（稀释后）CTRERIGL
| Q4 25 | $0.52 | $14.11 | ||
| Q3 25 | $0.35 | $1.46 | ||
| Q2 25 | $0.35 | $3.28 | ||
| Q1 25 | $0.35 | $0.63 | ||
| Q4 24 | $0.30 | $0.82 | ||
| Q3 24 | $0.21 | $0.70 | ||
| Q2 24 | $0.07 | $-0.06 | ||
| Q1 24 | $0.22 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $198.0M | $155.0M |
| 总债务越低越好 | $894.2M | $52.5M |
| 股东权益账面价值 | $4.0B | $391.5M |
| 总资产 | $5.1B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.22× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CTRERIGL
| Q4 25 | $198.0M | $155.0M | ||
| Q3 25 | $712.5M | $137.1M | ||
| Q2 25 | $306.1M | $108.4M | ||
| Q1 25 | $26.5M | $77.1M | ||
| Q4 24 | $213.8M | $77.3M | ||
| Q3 24 | $377.1M | $61.1M | ||
| Q2 24 | $495.1M | $49.1M | ||
| Q1 24 | $451.2M | $49.5M |
总债务CTRERIGL
| Q4 25 | $894.2M | $52.5M | ||
| Q3 25 | $893.8M | $60.0M | ||
| Q2 25 | $1.2B | $60.0M | ||
| Q1 25 | $822.1M | $60.0M | ||
| Q4 24 | $396.9M | $60.0M | ||
| Q3 24 | $396.7M | $60.0M | ||
| Q2 24 | $671.1M | $60.0M | ||
| Q1 24 | $595.9M | $60.0M |
股东权益CTRERIGL
| Q4 25 | $4.0B | $391.5M | ||
| Q3 25 | $4.0B | $117.6M | ||
| Q2 25 | $3.3B | $81.9M | ||
| Q1 25 | $2.9B | $18.6M | ||
| Q4 24 | $2.9B | $3.3M | ||
| Q3 24 | $2.4B | $-14.6M | ||
| Q2 24 | $1.9B | $-29.9M | ||
| Q1 24 | $1.7B | $-31.7M |
总资产CTRERIGL
| Q4 25 | $5.1B | $513.6M | ||
| Q3 25 | $5.1B | $242.5M | ||
| Q2 25 | $4.7B | $206.7M | ||
| Q1 25 | $3.9B | $176.0M | ||
| Q4 24 | $3.4B | $164.0M | ||
| Q3 24 | $2.9B | $139.4M | ||
| Q2 24 | $2.7B | $128.4M | ||
| Q1 24 | $2.3B | $126.5M |
负债/权益比CTRERIGL
| Q4 25 | 0.22× | 0.13× | ||
| Q3 25 | 0.22× | 0.51× | ||
| Q2 25 | 0.35× | 0.73× | ||
| Q1 25 | 0.28× | 3.23× | ||
| Q4 24 | 0.14× | 18.25× | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $394.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 3.54× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CTRERIGL
| Q4 25 | $394.0M | $22.0M | ||
| Q3 25 | $100.9M | $24.0M | ||
| Q2 25 | $100.8M | $30.5M | ||
| Q1 25 | $71.4M | $-893.0K | ||
| Q4 24 | $244.3M | $14.5M | ||
| Q3 24 | $67.2M | $21.7M | ||
| Q2 24 | $53.0M | $302.0K | ||
| Q1 24 | $48.8M | $-5.0M |
现金转化率CTRERIGL
| Q4 25 | 3.54× | 0.08× | ||
| Q3 25 | 1.35× | 0.86× | ||
| Q2 25 | 1.47× | 0.51× | ||
| Q1 25 | 1.08× | -0.08× | ||
| Q4 24 | 4.68× | 1.01× | ||
| Q3 24 | 2.01× | 1.75× | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
